)
Marksans Pharma (MARKSANS) investor relations material
Marksans Pharma Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 FY26 operating revenue reached INR 754 crore, up 10.6% YoY, driven by strong execution, robust US order book, and seasonal demand, with margin expansion from lower raw material costs and favorable currency movements.
UK business stabilized after prior pricing pressures, aided by new launches and currency tailwinds.
New subsidiaries were established in Ireland and Canada to strengthen global presence and support long-term growth.
Standalone and consolidated unaudited financial results for the quarter and nine months ended 31 December 2025 were reviewed and approved by the Board, with auditors expressing an unmodified conclusion.
Financial highlights
Q3 FY26 consolidated revenue: INR 754.4 crore (up 10.6% YoY); 9M FY26 revenue: INR 2,094.8 crore (up 9.54% YoY); US & North America: INR 412.4 crore (up 16.9% YoY); UK & EU: INR 258.2 crore (flat YoY); Australia/NZ: INR 61.4 crore (up 30.1% YoY).
Gross profit: INR 438.2 crore (up 14.3% YoY); gross margin: 58.1% (up 184 bps YoY); EBITDA: INR 160.7 crore (up 23.2% YoY); EBITDA margin: 21.3% (up 217 bps YoY).
Profit after tax: INR 113.7 crore (up 8.2% YoY); EPS: INR 2.5.
Cash from operations (9M): INR 263.2 crore; Capex: INR 97 crore; R&D spend: INR 62 crore (3% of revenue); cash balance: INR 824.2 crore; company remains debt-free.
Standalone revenue for the quarter: INR 3,397.29 million; standalone profit after tax: INR 609.12 million.
Outlook and guidance
US order book remains strong at $220M+, supporting optimism for near-term growth; targeting 20% growth in US for the upcoming year.
Strategic goal to reach INR 4,000 crore revenue in 2–3 years, with INR 5,000 crore as the next milestone.
Management expects growth momentum to continue for the rest of FY26, aiming for INR 3,000 crore revenue in the near term.
Europe and Canada expected to contribute meaningfully in 3–5 years, with 2026 as a turning point for Europe via M&A.
Employee costs expected to stabilize as hiring plateaus and capacity utilization rises.
- Q1 FY25 saw double-digit revenue and profit growth, margin gains, and new facility ramp-up.MARKSANS
Q1 24/252 Feb 2026 - Q2 FY25 delivered strong revenue and margin growth, led by US gains and Teva facility ramp-up.MARKSANS
Q2 24/2514 Jan 2026 - Record Q3 PAT and robust U.S. growth drive strong results and positive outlook.MARKSANS
Q3 24/2523 Dec 2025 - Revenue up 5% with margin gains, but profits fell on one-offs and UK price pressure.MARKSANS
Q1 25/2624 Nov 2025 - Record FY25 profit and revenue, strong US and OTC growth, and a robust outlook for FY26.MARKSANS
Q4 24/2519 Nov 2025 - Q2 FY26 delivered 16% revenue and 70% net profit growth QoQ, with strong cash flow and OTC focus.MARKSANS
Q2 25/2614 Nov 2025
Next Marksans Pharma earnings date
Next Marksans Pharma earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)